Physician profile
Mary Lindsey
NPI 1508208992
$14,202.11
in general payments reported to CMS, 2019-2025
35 companies · $2,356 in 2025
The $2,356 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $1,563 · 2021: $2,288 · 2022: $1,697 · 2023: $1,831 · 2024: $2,713 · 2025: $2,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,900.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,181.00 | 2019-2025 | |
| Amgen INC. | $2,294.41 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,070.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $978.16 | 2019-2025 | Benlysta |
| Pfizer INC. | $952.25 | 2020-2025 | |
| Janssen Biotech, INC. | $636.42 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $533.77 | 2023-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $523.88 | 2019-2025 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $419.23 | 2020-2025 | Orencia |
| Lilly USA, LLC | $335.87 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $297.11 | 2019-2020 | |
| Corcept Therapeutics | $220.02 | 2019-2020 | |
| Genzyme Corporation | $219.76 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $219.43 | 2021-2025 | Saphnelo |
| Sobi, INC | $201.07 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $155.18 | 2022-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $151.18 | 2023-2025 | Idacio |
| Novo Nordisk INC | $109.79 | 2020-2022 | |
| Genentech USA, INC. | $83.78 | 2019-2025 | Actemra |
| Mallinckrodt Hospital Products INC. | $79.23 | 2022-2023 | Acthar |
| Alexion Pharmaceuticals, INC. | $77.26 | 2024 | Strensiq |
| Sandoz INC. | $73.05 | 2023-2024 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $61.28 | 2024-2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $54.97 | 2024 | Arcalyst |
| Xeris Pharmaceuticals, INC. | $53.27 | 2021-2022 | |
| Horizon Therapeutics Plc | $31.50 | 2022 | |
| Tonix Medicines, INC. | $31.11 | 2025 | Tonmya |
| Radius Health, INC. | $26.36 | 2023 | |
| Insulet Corporation | $23.11 | 2020 | |
| Amarin Pharma, INC. | $21.55 | 2019 | |
| Sumitomo Pharma America, INC. | $20.70 | 2023 | Gemtesa |
| Shire North American Group INC | $18.78 | 2019 | |
| Celgene Corporation | $17.96 | 2019 | |
| Grt US Holding, INC. | $15.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Lindsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.